About CLINUVEL

Preclinical Testing

Preclinical tests assess the toxicity of a drug and examine its potential effects on the human body. The tests are conducted in-vitro (within the glass- test tubes, Petri dishes etc) and in-vivo (within the living - animal testing). These tests are required by pharmaceutical regulators to ensure that a drug is safe for human use prior to beginning human clinical trials.

Lab1
Preclinical testing in the lab

In-vivo trials may involve Pharmacokinetic (PK) and Pharmacodynamic (PD) studies, to begin to ascertain the drug's mechanism of action. PK and PD trials study what a body does to the drug and what a drug does to a body, respectively.  

Also investigated through pre-clinical trials is a drugs No Observable Effect Level (NOEL). This forms the starting point for subsequent trials and is the level at which the drug is dosed in amounts too small to have any measurable effect.

Latest Company Announcements

10 January 2018

Chair Letter to Shareholders

Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead.

Read More
21 December 2017

CLINUVEL Newsletter - December 2017

In the last communiqué of the calendar year, we take a breath and contemplate CLINUVEL’s status, a holding position for our teams over Christmas in the run up to a full 2018.

Read More
20 December 2017

Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England

CLINUVEL PHARMACEUTICALS LTD today announced that the first draft assessment from England’s National Institute for Health and Care Excellence (NICE) has been published,

Read More
07 December 2017

CLINUVEL Newsletter - December 2017

The CLINUVEL team is looking with much optimism and energy to the start of 2018.

Read More
05 December 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
05 December 2017

Appendix 3Z - Final Director’s Interest Notice

Final Director’s Interest Notice

Read More

Quick Links